• 02
  • 01
‘Personalize My Treatment’ (PMT) Initiative aims to:
• Make Canada’s rich scientific resources accessible to the research community
• Create a comprehensive cancer database of tissue samples, genomic data and clinical
data from the cancer patient population
• Match patients to available clinical trials based on the profile of their cancer

Moncton, New Brunswick - April 18, 2016 - At an announcement made earlier today at the Dr. Georges-L.-Dumont University Hospital Centre, Merck, known as MSD outside the United States and Canada, confirmed its commitment to research and innovation in oncology by contributing a total of $2 million to the Exactis Innovation ‘Personalize My Treatment’ (PMT) initiative. In addition, the Cancer Research Society (CRS) and the New Brunswick Health Research Foundation (NBHRF) will also contribute $1 million each to help bring innovative precision medicine to Canadians living with cancer.

Twitter

Archived Articles

btn campain EN
Atlantic Cancer Research Institute 
Pavillon Hôtel-Dieu
35, Providence Street
Moncton, NB E1C 8X3 Canada

info@canceratl.ca
Tel.: 506-862-7512
Fax.: 506-862-7571

Cover FR
Our annual report
Download PDF bullet blanc
Help Hélène Eusanio reach her goal. Make a donation today!
Helene

The Atlantic Cancer Research Institute

 (ACRI) is a non-profit organization founded in late 1998 and housed at the Dr. Georges-L.-Dumont University Hospital Centre in Moncton. Thanks to its unique expertise, ACRI has become a true centre of excellence in cancer research.

Our Partners

logo excipio logo chudumont logo soricimedlogo neplogo ccslogo umonctonlogo unblogo vitalitelogo conceptia